References
- 1. D. McTavish, K. L. Goa and M. Ferrill, Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy, Drugs39 (1990) 552–574; https://doi.org/10.2165/00003495-199039040-0000610.2165/00003495-199039040-00006
- 2. F. Register, Proposal to withdraw approval of two new drug applications and one abbreviated new drug application; opportunity for a hearing. Food and Drug Administration [Docket No. 96N-0512], Federal Register62 (1997) 2–9.
- 3. T. J. MacConnell and A. J. Stanners, Torsades de pointes complicating treatment with terfenadine, BMJ302 (1991) 1469; https://doi.org/10.1136/bmj.302.6790.1469-b10.1136/bmj.302.6790.1469-b
- 4. K. Kamiya, R. Niwa, M. Morishima, H. Honjo and M. C. Sanguinetti, Molecular determinants of hERG channel block by terfenadine and cisapride, J. Pharmacol. Sci. 108 (2008) 301–307; https://doi.org/10.1254/jphs.08102fp10.1254/jphs.08102FP
- 5. H. R. Lu, A. N. Hermans and D. J. Gallacher, Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?, Br. J. Pharmacol. 166 (2012) 1490–1502; https://doi.org/10.1111/j.1476-5381.2012.01880.x10.1111/j.1476-5381.2012.01880.x
- 6. C. Valenzuela, E. Delpon, L. Franqueza, P. Gay, J. Vicente and J. Tamargo, Comparative effects of nonsedating histamine H1 receptor antagonists, ebastine and terfenadine, on human Kv1.5 channels, Eur. J. Pharmacol. 326 (1997) 257–263; https://doi.org/10.1016/s0014-2999(97)85421-010.1016/S0014-2999(97)85421-0
- 7. I. S. Chen, C. Liu, M. Tateyama, I. Karbat, M. Uesugi, E. Reuveny and Y. Kubo, Non-sedating antihistamines block G-protein-gated inwardly rectifying K(+) channels, Br. J. Pharmacol. 176 (2019) 3161–3179; https://doi.org/10.1111/bph.1471710.1111/bph.14717669264031116876
- 8. E. Hadzijusufovic, B. Peter, K. V. Gleixner, K. Schuch, W. F. Pickl, T. Thaiwong, V. Yuzbasiyan-Gurkan, I. Mirkina, M. Willmann and P. Valent, H1-receptor antagonists terfenadine and lorata-dine inhibit spontaneous growth of neoplastic mast cells, Exp. Hematol. 38 (2010) 896–907; https://doi.org/10.1016/j.exphem.2010.05.00810.1016/j.exphem.2010.05.008433797120570632
- 9. F. Nicolau-Galmes, A. Asumendi, E. Alonso-Tejerina, G. Perez-Yarza, S. M. Jangi, J. Gardeazabal, Y. Arroyo-Berdugo, J. M. Careaga, J. L. Diaz-Ramon, A. Apraiz and M. D. Boyano, Terfenadine induces apoptosis and autophagy in melanoma cells through ROS-dependent and -independent mechanisms, Apoptosis16 (2011) 1253–1267; https://doi.org/10.1007/s10495-011-0640-y10.1007/s10495-011-0640-y320400121861192
- 10. W. T. Wang, Y. H. Chen, J. L. Hsu, W. J. Leu, C. C. Yu, S. H. Chan, Y. F. Ho, L. C. Hsu and J. H. Guh, Terfenadine induces anti-proliferative and apoptotic activities in human hormone-refractory prostate cancer through histamine receptor-independent Mcl-1 cleavage and Bak up-regulation, Naunyn Schmiedebergs Arch. Pharmacol. 387 (2014) 33–45; https://doi.org/10.1007/s00210-013-0912-x10.1007/s00210-013-0912-x24048439
- 11. P. Fernandez-Nogueira, A. Noguera-Castells, G. Fuster, L. Recalde-Percaz, N. Moragas, A. Lopez-Plana, E. Enreig, P. Jauregui, N. Carbo, V. Almendro, P. Gascon, P. Bragado and M. Mancino, Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer, Cancer Lett. 424 (2018) 70–83; https://doi.org/10.1016/j.canlet.2018.03.01410.1016/j.canlet.2018.03.01429548821
- 12. L. An, D. D. Li, H. X. Chu, Q. Zhang, C. L. Wang, Y. H. Fan, Q. Song, H. D. Ma, F. Feng and Q. C. Zhao, Terfenadine combined with epirubicin impedes the chemo-resistant human non-small cell lung cancer both in vitro and in vivo through EMT and Notch reversal, Pharmacol. Res. 124 (2017) 105–115; https://doi.org/10.1016/j.phrs.2017.07.02110.1016/j.phrs.2017.07.02128754458
- 13. H. Hibino, A. Inanobe, K. Furutani, S. Murakami, I. Findlay and Y. Kurachi, Inwardly rectifying potassium channels: their structure, function, and physiological roles, Physiol. Rev. 90 (2010) 291–366; https://doi.org/10.1152/physrev.00021.200910.1152/physrev.00021.200920086079
- 14. P. Sulaiman, Y. Xu, M. E. Fina, S. R. Tummala, H. Ramakrishnan, A. Dhingra and N. Vardi, Kir2.4 surface expression and basal current are affected by heterotrimeric G-proteins, J. Biol. Chem. 288 (2013) 7420–7429; https://doi.org/10.1074/jbc.M112.41279110.1074/jbc.M112.412791359164923339194
- 15. C. D. Ji, Y. X. Wang, D. F. Xiang, Q. Liu, Z. H. Zhou, F. Qian, L. Yang, Y. Ren, W. Cui, S. L. Xu, X. L. Zhao, X. Zhang, Y. Wang, P. Zhang, J. M. Wang, Y. H. Cui and X. W. Bian, Kir2.1 Interaction with Stk38 promotes invasion and metastasis of human gastric cancer by enhancing MEKK2-MEK1/2-ERK1/2 signaling, Cancer Res. 78 (2018) 3041–3053; https://doi.org/10.1158/0008-5472.CAN-17-377610.1158/0008-5472.CAN-17-3776811178829549164
- 16. H. Liu, J. Huang, J. Peng, X. Wu, Y. Zhang, W. Zhu and L. Guo, Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway, Mol. Cancer14 (2015) 59; https://doi.org/10.1186/s12943-015-0298-010.1186/s12943-015-0298-0437312825880778
- 17. I. Lee, S. J. Lee, T. M. Kang, W. K. Kang and C. Park, Unconventional role of the inwardly rectifying potassium channel Kir2.2 as a constitutive activator of RelA in cancer, Cancer Res. 73 (2013) 1056–1062; https://doi.org/10.1158/0008-5472.CAN-12-249810.1158/0008-5472.CAN-12-249823269273
- 18. X. Y. Wu and X. Y. Yu, Overexpression of KCNJ4 correlates with cancer progression and unfavorable prognosis in lung adenocarcinoma, J. Biochem. Mol. Toxicol. 33 (2019) e22270; https://doi.org/10.1002/jbt.2227010.1002/jbt.2227030512237
- 19. M. A. van der Heyden, A. Stary-Weinzinger and J. A. Sanchez-Chapula, Inhibition of cardiac inward rectifier currents by cationic amphiphilic drugs, Curr. Mol. Med. 13 (2013) 1284–1298; https://doi.org/10.2174/1566524011313999004310.2174/1566524011313999004323448372
- 20. P. Thomas and T. G. Smart, HEK293 cell line: a vehicle for the expression of recombinant proteins, J. Pharmacol. Toxicol. Methods. 51 (2005) 187–200; https://doi.org/10.1016/j.vascn.2004.08.01410.1016/j.vascn.2004.08.01415862464
- 21. X. Du, H. Zhang, C. Lopes, T. Mirshahi, T. Rohacs and D. E. Logothetis, Characteristic interactions with phosphatidylinositol 4,5-bisphosphate determine regulation of kir channels by diverse modulators, J. Biol. Chem. 279 (2004) 37271–37281; https://doi.org/10.1074/jbc.M40341320010.1074/jbc.M40341320015155739
- 22. S. Przestalski, J. Sarapuk, H. Kleszczynska, J. Gabrielska, J. Hladyszowski, Z. Trela and J. Kuczera, Influence of amphiphilic compounds on membranes, Acta Biochim. Pol. 47 (2000) 627–638.10.18388/abp.2000_3984
- 23. J. J. Babcock and M. Li, hERG channel function: beyond long QT, Acta Pharmacol. Sin. 34 (2013) 329–335; https://doi.org/10.1038/aps.2013.610.1038/aps.2013.6358791523459091
- 24. G. D’Alessandro, M. Catalano, M. Sciaccaluga, G. Chece, R. Cipriani, M. Rosito, A. Grimaldi, C. Lauro, G. Cantore, A. Santoro, B. Fioretti, F. Franciolini, H. Wulff and C. Limatola, KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo, Cell Death Dis. 4 (2013) e773; https://doi.org/10.1038/cddis.2013.27910.1038/cddis.2013.279376344123949222
- 25. M. Nunez, V. Medina, G. Cricco, M. Croci, C. Cocca, E. Rivera, R. Bergoc and G. Martin, Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDAMB-231, BMC Pharmacol. Toxicol. 14 (2013) 6; https://doi.org/10.1186/2050-6511-14-610.1186/2050-6511-14-6355838623311706